Shoulder Innovations Expands Humeral Stem Portfolio with Full Launch of I-135RFX — Shoulder Innovations, Inc.

Event summary

Shoulder Innovations launched the InSet™ I-135RFX Humeral Stem on April 27, 2026, following FDA 510(k) clearance for expanded fracture indications.
The product is the third addition to the I-Series humeral stem line, joining the InSet™ 95 (2024) and InSet™ 70 (2025).
The I-135RFX supports all primary, revision, and fracture total shoulder arthroplasty procedures.
Surgeons highlight its ease of use, straightforward technique, and integration with the company’s two-tray surgical instrumentation system.

The big picture

Shoulder Innovations is solidifying its position in the shoulder arthroplasty market with the full launch of the I-135RFX, expanding its I-Series portfolio. The company’s focus on procedural efficiency and surgeon collaboration aligns with broader industry trends toward minimally invasive and outcome-driven surgical solutions. The rapid succession of product launches underscores its commitment to innovation, but maintaining this momentum will be critical in a competitive medical device landscape.

What we're watching

Market Adoption: How quickly the I-135RFX gains traction among surgeons following its full commercial launch.
Competitive Positioning: Whether Shoulder Innovations can sustain its innovation pace to maintain a competitive edge in the shoulder arthroplasty market.
Regulatory Expansion: The pace at which the company secures additional FDA clearances for other indications.